Sirnaomics Ltd. (HK:2257)
:2257
Want to see HK:2257 full AI Analyst Report?
2257 Stock Chart & Stats
HK$8.00
-HK$0.09(-2.79%)
At close: 4:00 PM EST
HK$8.00
-HK$0.09(-2.79%)
Day’s Range― - ―
52-Week RangeHK$3.56 - HK$22.78
Previous CloseN/A
Volume36.40K
Average Volume (3M)442.62K
Market Cap
HK$589.20M
Enterprise ValueHK$78.06M
Total Cash (Recent Filing)HK$13.52M
Total Debt (Recent Filing)HK$9.31M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding109,721,535
10 Day Avg. Volume408,789
30 Day Avg. Volume442,620
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-9.39
Price to Sales (P/S)0.00
P/FCF Ratio-10.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$162.00M
Bulls Say, Bears Say
Bulls Say
Focused RNAi Therapeutic PlatformA clear, technology-driven focus on siRNA therapeutics and delivery provides a durable strategic position: RNAi is a differentiated modality with high barriers to entry (expertise, delivery know-how). That specialization supports long-term partnerships and value capture if clinical progress continues.
Improving Cash Burn TrendA material reduction in cash burn over consecutive years extends operating runway and lowers near-term refinancing pressure. Sustained improvement in cash consumption allows management more time to advance programs and de-risk assets before needing dilutive financing or costly debt.
Smaller Net Loss In 2025A meaningful reduction in net loss signals progress on cost control or program execution. If durable, this trend improves financial flexibility, reduces future funding needs, and indicates the company may be moving toward a more sustainable operating model as programs advance.
Bears Say
Revenue Collapsed To ZeroAbsence of recurring revenue is a structural weakness for sustaining R&D and operations. Without commercial receipts, the firm depends on external capital or partnerships. Over months, that limits self-funding ability and magnifies financing and execution risk until commercialization or licensing occurs.
Negative Shareholder EquityNegative equity materially weakens balance-sheet flexibility: it constrains borrowing capacity, complicates counterpart relationships, and raises dilution/refinancing risk. This persistent impairment is a long-term capital-structure concern for sustaining R&D-intensive programs.
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the company is not self-funding its development. Even with improved burn, ongoing cash deficits require external funding, increasing execution risk and potential dilution until a durable revenue or partner-based funding source is secured.
Sirnaomics Ltd. News
2257 FAQ
What was Sirnaomics Ltd.’s price range in the past 12 months?
Sirnaomics Ltd. lowest stock price was HK$3.56 and its highest was HK$22.78 in the past 12 months.
What is Sirnaomics Ltd.’s market cap?
Sirnaomics Ltd.’s market cap is HK$589.20M.
When is Sirnaomics Ltd.’s upcoming earnings report date?
Sirnaomics Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 83 days.
How were Sirnaomics Ltd.’s earnings last quarter?
Sirnaomics Ltd. released its earnings results on Mar 27, 2026. The company reported -HK$0.881 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.881.
Is Sirnaomics Ltd. overvalued?
According to Wall Street analysts Sirnaomics Ltd.’s price is currently Overvalued.
Does Sirnaomics Ltd. pay dividends?
Sirnaomics Ltd. does not currently pay dividends.
What is Sirnaomics Ltd.’s EPS estimate?
Sirnaomics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sirnaomics Ltd. have?
Sirnaomics Ltd. has 109,721,535 shares outstanding.
What happened to Sirnaomics Ltd.’s price movement after its last earnings report?
Sirnaomics Ltd. reported an EPS of -HK$0.881 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.516%.
Which hedge fund is a major shareholder of Sirnaomics Ltd.?
Currently, no hedge funds are holding shares in HK:2257
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sirnaomics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.69%
12-Months-Change
Fundamentals
Return on Equity
191.92%
Trailing 12-Months
Asset Growth
-27.12%
Trailing 12-Months
Company Description
Sirnaomics Ltd.
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Transcenta Holding Limited
―
Ascentage Pharma Group International
―